Analyst Ratings For Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
Today, JPMorgan Chase & Co. initiated coverage on Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) with a Overweight with a price target of $14.00.
There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) is Buy with a consensus target price of $23.00 per share, a potential 181.52% upside.
Some recent analyst ratings include
- 3/21/2019-Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has coverage initiated with a Overweight rating and $14.00 price target
- 9/4/2018-Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) gets downgraded to Market Perform by Wells Fargo & Co
- 6/14/2018-Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has coverage initiated with a Outperform rating and $21.00 price target
- 4/24/2018-Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has coverage initiated with a Outperform ➝ Outperform rating and $37.00 price target
- On 9/27/2018 Aaron Schuchart, Insider, sold 6,000 with an average share price of $9.50 per share and the total transaction amounting to $57,000.00.
- On 5/10/2018 Bioventures Ltd Novartis, Major Shareholder, sold 73,955 with an average share price of $10.12 per share and the total transaction amounting to $748,424.60.
- On 5/7/2018 Bioventures Ltd Novartis, Major Shareholder, sold 15,548 with an average share price of $10.11 per share and the total transaction amounting to $157,190.28.
- On 12/8/2017 Anthony G Quinn, CEO, bought 8,288 with an average share price of $4.96 per share and the total transaction amounting to $41,108.48.
- On 12/6/2017 Anthony G Quinn, CEO, bought 4,888 with an average share price of $4.92 per share and the total transaction amounting to $24,048.96.
- On 12/5/2017 Charles N York II, CFO, bought 25,959 with an average share price of $4.48 per share and the total transaction amounting to $116,296.32.
- On 12/4/2017 Anthony G Quinn, Director, bought 7,956 with an average share price of $4.98 per share and the total transaction amounting to $39,620.88.
About Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Recent Trading Activity for Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
Shares of Aeglea Bio Therapeutics Inc closed the previous trading session at 8.16 up +0.070 0.87% with 8.15 shares trading hands.
